Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors.
AMG-510 racemate, is a racemic mixture of AMB-510, which is a potent KRAS G12C covalent inhibitor. AMG-510 selectively targets the KRAS p.G12C mutant, at either the DNA, RNA or protein level, and prevents, through an as of yet not elucidated manner, expression of and/or tumor cell signaling through the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. Note: According to Sci-Finder database, CAS#2252403-56-6 is a AMG510 active atropisomer. Many vendor mistakenly listed CAS#2296729-00-3 as the AMG510 active atropisomer.
Ras Related Products:
Ketoconazole; (Rac)-Antineoplaston A10; CID-1067700; Kobe0065; Kobe-2602; ML141; Zoledronic acid; Lonafarnib; Adagrasib; Deltarasin; Salirasib; EHop-016; CCG-1423; ZCL-278; 6H05; 1A-116